The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (18 F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors.

Mei Sim LungRodney J HicksNick PavlakisEmma LinkMichael JeffordBenjamin ThomsonDavid K WyldWinston LiauwTimothy AkhurstNarmatha KuruMichael Michael

Published in: Asia-Pacific journal of clinical oncology (2020)

Everolimus is active with prolonged disease control in poor prognosis FDG-avid G2 PNETs. Treatment individualization based on functional imaging warrants further evaluation.

Keyphrases

positron emission tomography
poor prognosis
phase ii study
computed tomography
neuroendocrine tumors
long non coding rna
pet ct
pet imaging
open label
high resolution
locally advanced
health information
clinical trial
randomized controlled trial
healthcare
squamous cell carcinoma
radiation therapy
rectal cancer